Centralised Pan-Algerian Survey on the Undertreatment of Hypercholesterolemia

Completed

• Conditions: Hypercholesterolemia; Cardiovascular Disease; Peripheral Arterial Disease; Hypertension; Coronary Heart Disease; Diabetes

• Registration Number: NCT01768403
• Lead Sponsor: AstraZeneca

Brief Summary

Centralized Pan-Algerian Survey on the undertreatment of hypercholesterolemia. The purpose of this study is to establish the proportion of patients on lipid-lowering pharmacological treatment reaching the LDL-C goals according to the Third Joint European Task Force guidelines in the survey population.

Detailed Description

Centralised Pan-Algerian Survey on the undertreatment of hypercholesterolemia.

Study Timeline

• Study Start: 2010-09
• Primary Completion: 2011-03
• Study Completion: 2011-03
• Status Verified: 2013-01
• Study First Submitted: 2013-01-14
• Study First Submitted QC: 2013-01-14
• Last Update Submitted: 2013-01-14
• Study First Posted: 2013-01-15
• Last Update Posted: 2013-01-15

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 1236

Inclusion Criteria

• Subject must provide informed consent and comply with the survey procedures.
• Subject is on lipid lowering drug treatment for at least 3 months, with no dose change for a minimum of 6 weeks.

Exclusion Criteria

• Subjects who are unwilling or unable to provide informed consent.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Number and percentage of subjects achieving the LDL-C goals, according to the Third Joint European Task Force (TJETF) guidelines.	24 weeks

Secondary Outcome Measures

Name	Time	Method
The association between achievement of LDL-C goals, according to the Third Joint European Task Force / NCEP ATP III / 2004 updated NCEP ATP III guidelines, and patient and physician variables, assessed by multivariate logistic regression models	24 weeks
Number and percentage of subjects achieving LDL-C goals according to the NCEP ATP III/2004 updated NCEP ATP III and to the 2005 AFSSAPS guidelines	24 weeks	Overall and in the following sub-populations: Patients with/or without metabolic syndrome-Iary/IIary preven
Number and percentage of subjects achieving LDL-C goals according to the TJETF guidelines.	24 weeks	In the following sub-populations: - Patients with / or not with metabolic syndrome (according to NCEP III definition), - Primary/secondary prevention patients
Number and percentage of subjects achieving LDL-C goals according to the : TJETF / NCEP ATP III and 2004 updated NCEP ATP III guidelines.	24 weeks	For the following sub-populations: Demographic variables, CV risk factors \& Lipid-lowering agent class